الفهرس 
H EPATITIS C V IRUSOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Background: prevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population FDA has approved ombitasvir/paritaprevir/ ritonavir for the treatment of patients with severe renal disease. Aim of the Work: to evaluate the efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in treatment of chronic Hepatitis C Egyptian Prevelant Hemodialysis patients to compare it with the same treatment result in chronic Hepatitis C Egyptian patients with normal renal functions. Patients and methods: Written informed consent was obtained from all patients participating in the study .This case-control study was conducted on one hundred patients with confirmed diagnosis of HCV positive infection at Center of National Committee for Control of Viral Hepatitis [NCCVH] at Ain Shams University Hospital. Patients were divided into two groups group I (Control Group): 50 chronic Hepatitis C virus patients with normal renal functions group II (Case Group) 50 chronic Hepatitis C virus Prevelant Hemodialysis patients on regular hemodialysis. Results: 95.1% of Prevelant Hemodialysis patients achieved Sustained Virological Response (SVR) while 100% of patients with normal kidney functions achieved Sustained Virological Response. Most common side effects were Hemoglobin drop, GIT disturbance, Sever fatigue and Itching. Conclusion: Ombitasvir, paritaprevir, and ritonavir considered as a safe and effective in treatment in HCV infection in patients on regular hemodialysis